Skip to search formSkip to main contentSkip to account menu

DX 8951

Known as: DX-8951 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

exatecan

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
DS-8201a, a HER2-targeting antibody-drug conjugate, to elicit immune responses and benefits in combination with an anti-PD-1 antibody.
1031Background: DS-8201a, a HER2-targeting antibody–drug conjugate (ADC), with a topoisomerase I inhibitor, exatecan drivative… 
Review
2008
Review
2008
Key role of topoisomerase I inhibitors in the treatment of recurrent and refractory epithelial ovarian carcinoma
Ovarian cancer remains one of the most difficult gynecologic cancers to treat, owing to its aggressive biology and high relapse… 
2007
2007
Quantitative acid hydrolysis of DE-310, a macromolecular carrier system for the camptothecin analog DX-8951f.
2005
2005
DE-310, a macromolecular prodrug of the topoisomerase-I-inhibitor exatecan (DX-8951), in patients with operable solid tumors
Background: DE-310 is composed of the topoisomerase-I-inhibitor DX-8951 (exatecan) and a biodegradable macromolecular carrier… 
2005
2005
A possible mechanism for the long-lasting antitumor effect of the macromolecular conjugate DE-310: mediation by cellular uptake and drug release of its active camptothecin analog DX-8951
DE-310, a new macromolecular prodrug, was designed to enhance the pharmacological profiles of a novel camptothecin analog (DX… 
2005
2005
Examination of meningocele induced by the antitumor agent DE-310 in rat fetuses.
2004
2004
A Phase II Study of Intravenous Exatecan Mesylate (DX-8951f) Administered Daily for Five Days Every Three Weeks to Patients with Metastatic Adenocarcinoma of the Colon or Rectum
Background: To evaluate the antitumor activity, toxicities, and pharmacokinetics (PK) of DX-8951f administered as a 30-min… 
2004
2004
Pharmacokinetics of DE-310, a novel macromolecular carrier system for the camptothecin analog DX-8951f, in tumor-bearing mice.
To improve the distribution of the novel camptothecin analog DX-8951, DE-310, which is composed of DX-8951 covalently linked to a… 
2003
2003
A phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for 5 days every 3 weeks to patients with advanced ovarian, tubal or peritoneal cancer resistant to platinum, taxane…
BackgroundDX-8951f is a water-soluble camptothecin derivative with greater in vivo and in vitro activity than topotecan or… 
2001
2001
Urinary Metabolites of DX-8951, a Novel Camptothecin Analog, in Rats and Humans
Summary Urinary metabolites of DX-8951 ((1S,9S)-1-amino-9-ethyl-5-fluoro-1,2,3,9,12,15-hexahydro-9-hydroxy-4-methyl-10H,13H-benzo… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)